Brilinta Heart Attack Lawyers
- Accutane
- Actos
- Ambien
- Avandia
- Benicar
- Brilinta
- Celexa
- Codeine
- Crestor
- Darvocet/Darvon
- Demerol
- Depakote
- Dilaudid
- Fosamax
- Fresenius Blood Volumizer
- Gynecomastia
- Invega
- Levaquin
- Lexapro
- Lunesta
- Luvox
- Morphine
- Omontys
- OxyContin
- Paxil
- Percocet
- Pexeva
- Pradaxa
- Prilosec
- Propecia
- Risperdal
- Sonata
- SSRI Suicides
- Testosterone Replacement Therapy
- Topamax
- Ultram
- Vicodin
- Vicoprofen
- Wellbutrin
- Xarelto
- Xolair
- Yaz/Yasmin
- Zocor
- Zofran
- Zoloft
- Zyrtec
Dangerous Drugs
Brilinta (ticagrelor) is an anticoagulant (blood thinner) made by AstraZenica and approved by the FDA in July 2011 to help reduce the risk of stroke or cardiovascular problems in patients who have angina or who have had a heart attack in the past. Like all anticoagulants, Brilinta carries the risk of certain side effects. Some of these side effects may prove fatal to patients, including:
- Stroke
- Heart attack
- Internal bleeding
While patients must be advised of potential side effects of medications they take, claims have arisen that the makers of Brilinta were not honest about the likelihood or severity of Brilinta side effects when they sought FDA approval of this drug.
Falsified Brilinta Clinical Trial?
Multiple doctors and researchers have alerted the FDA to the fact that AstraZenica may have submitted false data to the agency in order to gain approval for Brilinta to be prescribed in the United States. This has led to a federal investigation into the validity of the PLATO study upon which FDA-approval of Brilinta was heavily based.
In April 2013, the International Journal of Cardiology published a study by doctors who claimed that irregularities in data presented in the PLATO trial made Brilinta appear to be safer than it is. Specifically, they claim that vital data regarding deaths and adverse events linked to Brilinta was omitted from the report submitted to the FDA: "An estimated 23 definite or possible cardiovascular events or deaths on ticagrelor (Brilinta) were either not submitted for adjudication, inactivated, deleted or were downgraded to 'softer' endpoints."
In the PLATO study, Brilinta was compared to the competitive anticoagulant Plavix. Researchers paid by AstraZenica allegedly reported that side effects common to both drugs were reported in such a way that they appeared more frequent and more problematic with Plavix than with Brilinta. Now, however, multiple respected experts claim that there are gaps in this reporting which could result in the injury or death of Brilinta patients.
Brilinta Lawsuits
If you or your loved one suffered a heart attack, stroke, or another serious cardiovascular event which you believe was a result of Brilinta side effects, you could be eligible to file a Brilinta lawsuit in pursuit of compensation for your medical expenses, suffering, and other damages. Contact a Brilinta lawyer today for a free and confidential legal consultation.